Seneca Biopharma (formerly NeuralStem) is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.